Minireview:Malasseziainfections in immunocompromised patients

Etiologic Agents of Candidemia in Pediatric Immunocompromised Patients

Abstract Background: Candidemia is the main cause of fungal nosocomial bloodstream infections and is related to meaningful mortality specially, in pediatrics. Mortality rate range from 5% to 71%, and it can reach as high as 81%. Delays in beginning of treatment have also been linked to intensified mortality. The epidemiology of Candida infection is changing from region to region. Regiona...

Norovirus in immunocompromised patients.

W hile undergoing a routine mammogram, Mrs. B, age 76 years and in good health, was found to have right axillary adenopathy. A core biopsy confirmed the diagnosis of follicular lymphoma and she was referred to an oncologist who recommended treatment with six cycles of bendamustine, mitoxantrone, and rituximab. She tolerated the treatment fairly well except for mild lower abdominal discomfort fo...

Vaccines in immunocompromised patients.

Investigation of pulmonary fungal infections in immunocompromised patients

Background: With increasing immunocompromised patients, fungal infections especially lung infection, have also increased. In this study, fungal contamination of the respiratory system in immunocompromised patients was evaluated. Methods: This descriptive cross-sectional study was conducted in immunocompromised patients suspicious of pulmonary infections referring to specialized lung clinic of ...

Antifungal Prophylaxis in Immunocompromised Patients

Invasive fungal infections (IFIs) represent significant complications in patients with hematological malignancies. Chemoprevention of IFIs may be important in this setting, but most antifungal drugs have demonstrated poor efficacy, particularly in the prevention of invasive aspergillosis. Antifungal prophylaxis in hematological patients is currently regarded as the gold standard in situations w...